Biogen's Diranersen Phase 2 Alzheimer's Study Shows Cognitive Benefit, Misses Primary Endpoint
BIIB sits 80% above its 52-week low of $119.18.
Summary
Biogen announced mixed topline results from its Phase 2 Celia study of Diranersen (BIIB080) for early Alzheimer's Disease. The study showed a robust reduction in tau pathology and a slowing of clinical decline across all doses, with a safety profile consistent with previous studies. However, the study notably did not meet its primary endpoint for dose response on the CDR-SB scale at week 76. These mixed efficacy signals present a complex picture for investors, as positive biological and cognitive trends are offset by the failure to meet the primary statistical endpoint. This news is highly material for Biogen, a major player in neuroscience, and will prompt close scrutiny of the company's strategic decisions regarding Diranersen's future development.
At the time of this announcement, BIIB was trading at $215.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $119.18 to $205.97. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.